Decision and Details
Nature of grant income
This is because the company entered into a subcontracted research and development agreement relating to a research and development project under AMED's Innovative Cancer Medical Research and Development Project for Practical Application.
The grant is scheduled to be recognized as non-operating income after the company receives a confirmation notice from AMED from the next fiscal year onward. There is no impact on the earnings forecast for the current fiscal year. The company will issue a further notice once the timing of recognition of the non-operating income has been determined.
| Item | Details |
|---|---|
| Matter Covered | Nature of grant income |
| Decision Date | 17 July 2026 (date of execution of the subcontracted research and development agreement) |
| Period Covered | For the fiscal year ending March 2027 |
| Amount | Grant: ¥30 million |
| Impact on Business Performance | The grant is scheduled to be recognized as non-operating income after the company receives a confirmation notice from AMED from the next fiscal year onward. There is no impact on the earnings forecast for the current fiscal year. The company will issue a further notice once the timing of recognition of the non-operating income has been determined. |
| Reason | This is because the company entered into a subcontracted research and development agreement relating to a research and development project under AMED's Innovative Cancer Medical Research and Development Project for Practical Application. |
| Future plans | The grant is scheduled to be recognized as non-operating income after the company receives a confirmation notice from AMED from the next fiscal year onward. The company will issue a further notice once the timing of recognition has been determined. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is because the company entered into a subcontracted research and development agreement for the nonclinical testing of a novel therapeutic drug for intractable tumors with RNA-splicing mutations under AMED's "Innovative Cancer Medical Research and Development Project for Practical Application."